A. van Oosterom

8.7k citations

88 papers · 6.7k indexed · 2 hit papers · h-index 34

Pulmonary and Respiratory Medicine top 0.2%
Gastroenterology top 0.05%
Oncology top 1%
Surgery top 2%
Molecular Biology top 10%

Co-authors: Jaap Verweij Jean‐Yves Blay Ian Judson M. van Glabbeke Raf Sciot Pancras C.W. Hogendoorn Maria Dêbiec‐Rychter Peter Reichardt
Topics: Sarcoma Diagnosis and Treatment (30 papers)Gastrointestinal Tumor Research and Treatment (22 papers)Vascular Tumors and Angiosarcomas (12 papers)
Cited by: Gastroenterology Pulmonary and Respiratory Medicine Oncology
Journals: The Lancet Journal of Clinical Oncology Gastroenterology
Partner nations: Belgium Netherlands United Kingdom

In The Last Decade

A. van Oosterom

87 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

2004 1.3k citations Jaap Verweij, Jean‐Yves Blay et al. profile →
Consensus meeting for the management of gastrointestinal stromal tumors  Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

2005 561 citations Jean‐Yves Blay, Heikki Joensuu et al. Annals of Oncology profile →

Peers

Countries citing papers authored by A. van Oosterom

Since Specialization

Citations

This map shows the geographic impact of A. van Oosterom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. van Oosterom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. van Oosterom more than expected).

Fields of papers citing papers by A. van Oosterom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. van Oosterom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. van Oosterom. The network helps show where A. van Oosterom may publish in the future.

Co-authorship network of co-authors of A. van Oosterom

This figure shows the co-authorship network connecting the top 25 collaborators of A. van Oosterom. A scholar is included among the top collaborators of A. van Oosterom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. van Oosterom. A. van Oosterom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 2012 ·Clinical Cancer Research ·José Baselga,Alain C. Mita,Patrick Schöffski,Herlinde Dumez,Federico Rojo,Josep Tabernero,Clifford DiLea,William Mietlowski,(unknown),(unknown),Margaret Dugan,Kathryn Parker,Eric Walk,A. van Oosterom,Erika Martinelli,Chris H. Takimoto	14
2	Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases 2008 ·Clinical Cancer Research ·Michael C. Heinrich,Heikki Joensuu,George D. Demetri,Christopher L. Corless,Jane F. Apperley,Jonathan A. Fletcher,Denis Soulières,Stephan Dirnhofer,Amy Harlow,Ajia Town,Arin McKinley,Shane G. Supple,John F. Seymour,Lilla Di Scala,A. van Oosterom,Richard Herrmann,Zariana Nikolova,(unknown)	151
3	Simultaneous determination of AMN107 and Imatinib (Gleevec®, Glivec®, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection 2006 ·Journal of Chromatography B ·Gunther Guetens,Hans Prenen,Gert De Boeck,A. van Oosterom,Patrick Schöffski,Martin Highley,E. A. de Bruijn	16
4	Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours 2006 ·European Journal of Cancer ·Maja J.A. de Jonge,Herlinde Dumez,Jaap Verweij,Shai Yarkoni,David S. Snyder,Denis Lacombe,Sandrine Marréaud,(unknown),Cornelis J.A. Punt,A. van Oosterom	79
5	Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants 2005 ·Gastroenterology ·Maria Dêbiec‐Rychter,Jan Cools,Herlinde Dumez,Raf Sciot,Michel Stul,Nicole Mentens,Hilde Vranckx,Bartosz Wasąg,Hans Prenen,Johannes Roesel,Anne Hagemeijer,A. van Oosterom,Peter Marynen	396
6	Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group 2004 ·Cancer Chemotherapy and Pharmacology ·Ian Judson,Peiming Ma,Bin Peng,Jaap Verweij,Amy Racine,Eugenio Donato Di Paola,M. van Glabbeke,Saša Dimitrijević,Michelle Scurr,Herlinde Dumez,A. van Oosterom	158
7	Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): a retrospective analysis 2002 ·Annals of Oncology ·Robert Paridaens,J. Wildiers,Herlinde Dumez,(unknown),Caroline Weltens,Walter Van den Bogaert,Erik Van Limbergen,An Aerts,(unknown),A. van Oosterom	8
8	Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum 2001 ·Cancer Gene Therapy ·Jan Theys,Willy Landuyt,Sandra Nuyts,Lieve Van Mellaert,A. van Oosterom,Philippe Lambin,Jozef Anné	75
9	Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E 2000 ·UCL Discovery (University College London) ·(unknown),P. Fumoleau,Hoffmann-La Roche,(unknown),Christian Dittrich,C.J.A. Punt,J.P. Droz,AH Calvert,A. van Oosterom,J. Wanders,M. Ravic	7
10	Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial 2000 ·Annals of Oncology ·Axel Le Cesne,Ian Judson,John Radford,Jean‐Yves Blay,A. van Oosterom,Sjoerd Rodenhuis,Paul Lorigan,(unknown),José Jimeno,Jaco J. Verweij	9
11	Dacarbazine, cisplatin and IFN-alpha with or without IL-2 in advanced melanoma (EORTC trial 18951) 2000 ·Annals of Oncology ·Ulrich Keilholz,C.J.A. Punt,M. Gore,(unknown),Payal T. Patel,D. Liénard,A. van Oosterom,Thomas M. Proebstle,A.M.M. Eggermont	15
12	Carcinoma of the Kidney, Testis, and Rare Urologic Malignancies 2000 ·American Journal of Clinical Oncology ·(unknown),Luc Baert,Luther W. Brady,Dirk De Ridder,Hans Goethuys,Rien J.M. Nijman,Raymond Oyen,Howard Ozer,Tania Roskams,John P. Stein,L Stockx,A. van Oosterom,H. P. Van Poppel,(unknown)	3
13	Vascular endothelial growth factor (VEGF): Plasma is the place to be 1998 ·Annals of Oncology ·Wim Wynendaele,Rita Derua,Marc Hoylaerts,Adam Pawinski,Etienne Waelkens,Ernst de Bruijn,Wilfried Merlevede,Robert Paridaens,A. van Oosterom	2
14	Late peritoneal metastasis in a patient with osteosarcoma 1998 ·Annals of Oncology ·(unknown),D. Schrijvers,Johan Somville,Paul Van Schil,Guy Hubens,A. van Oosterom	15
15	Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian Cancer 1995 ·JNCI Journal of the National Cancer Institute ·Martine Piccart,Martin Gore,W. ten Bokkel Huinink,A. van Oosterom,Jaco J. Verweij,J. Wanders,(unknown),M. Bayssas,S.B. Kaye	101
16	Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion 1995 ·Investigational New Drugs ·Luc Dirix,G. Catimel,René Verdonk,Ernst de Bruijn,Brigitte Tranchand,C Ardiet,A. van Oosterom	2
17	P-Glycoprotein: Clinical Significance and Methods of Analysis 1995 ·Critical Reviews in Clinical Laboratory Sciences ·(unknown),E. Gheuens,(unknown),A. van Oosterom,R. A. A. Maes,Grace Bradley	37
18	Coping with toxicities of docetaxel (TaxotereTM) 1993 ·Annals of Oncology ·D. Schrijvers,J. Wanders,Luc Dirix,A. Prové,(unknown),A. van Oosterom,S.B. Kaye	123
19	Tumor lysis syndrome in a patient with metastatic merkel cell carcinoma 1991 ·Cancer ·Luc Dirix,A. Prové,D. Becquart,E. Wouters,P. Vermeulen,A. van Oosterom	41
20	Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease 1990 ·European Journal of Cancer and Clinical Oncology ·G. Blackledge,A. van Oosterom,Henning T. Mouridsen,William P. Steward,J. Buesa,D. Thomas,R. Sylvester,Jacques Rouëssé	24

About A. van Oosterom

A. van Oosterom is a scholar working on Gastroenterology, Oncology and Pulmonary and Respiratory Medicine, having authored 88 papers that have together received 6.7k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (30 papers), Gastrointestinal Tumor Research and Treatment (22 papers) and Vascular Tumors and Angiosarcomas (12 papers). The work is most often cited by research in Gastroenterology (3.1k citations), Pulmonary and Respiratory Medicine (4.2k citations) and Oncology (1.8k citations). A. van Oosterom has collaborated with scholars based in Belgium, Netherlands and United Kingdom. Frequent co-authors include Jaap Verweij, Jean‐Yves Blay, Ian Judson, M. van Glabbeke, Raf Sciot, Pancras C.W. Hogendoorn, Maria Dêbiec‐Rychter, Peter Reichardt, Paolo G. Casali and Herlinde Dumez. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact